INS and rheumatoid arthritis: However, in a clinical study with patients suffering from rheumatoid arthritis, the monoclonal anti-TNF-α antibody adalimumab reduced CRP levels without significant alteration of insulin resistance [14], indicating that changes in overall inflammatory activity per se do not necessarily alter insulin sensitivity.